Melissa Hardesty, MD, MPH, Discusses the Focus of the 2021 Society of Gynecologic Oncology Annual Meeting

Article

Hardesty detailed her expectations for the focus of the conference and the exciting topical opportunities presented this year’s SGO Annual Meeting compared with past years.

Melissa Hardesty, MD, MPH, of the Alaska Women’s Cancer Care, spoke with CancerNetwork® regarding topics of discussion at the forefront of this year’s Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer.

Transcription:

This year, the meeting has focused on diversity and inclusiveness [by] really looking at some actual research about how these things impact our patients, how they impact our providers, racial bias, and all of that. There’s a lot of content that’s specifically trying to help us learn how to do better in these ways, to just continue on further conversations. I know that the program organizers have put a strong emphasis on that. There [are] exciting talks in the opening plenary that I think in meetings past might not have been selected for [presentation, and] focusing on the commitment to that area.

Recent Videos
Findings from David Rimm, MD, PhD, suggest that there may be an inverse relationship between HER2 and TROP2 expression among patients with breast cancer.
Tissue samples collected from patients with breast cancer during treatment may help explore therapy selection and predict toxicities.
The mechanism of CTO1681 may allow it to reduce the production of a broad range of proinflammatory cytokines in DLBCL.
Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.
Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Related Content